U.S was ImmunityBio’s largest region in fiscal 2025, bringing in $113.01M of $113.29M (100%).
| Geography | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| U.S | $42.00K | $31.00K | $14.21M | $113.01M | ||||||
| United States | — | — | — | — | ||||||
| Europe | $198.00K | $591.00K | $531.00K | $278.00K | ||||||
| Other Non-U.S | — | — | — | — | ||||||
| Total | $240.00K | $622.00K | $14.75M | $113.29M |
ImmunityBio brought in $113.29M from its two regions in fiscal 2025, the year ended December 31, 2025. That was up 668.3% from $14.75M in fiscal 2024. U.S was the largest at $113.01M (99.8%), ahead of Europe at $278.00K (0.2%).
From fiscal 2022 to 2025, combined revenue from these regions grew from $240.00K to $113.29M, a compound annual growth rate of 678.6%. U.S's share of the total rose from 17.5% to 99.8%.
Product Revenue, Net was ImmunityBio’s largest product and service line in fiscal 2025, bringing in $112.98M of $113.29M (100%).
| Product and Service | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Product Revenue, Net | — | — | $14.15M | $112.98M |
| Other Revenues | $240.00K | $622.00K | $595.00K | $306.00K |
| Total | $240.00K | $622.00K | $14.75M | $113.29M |
ImmunityBio brought in $113.29M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 668.3% from $14.75M in fiscal 2024. Product Revenue, Net was the largest at $112.98M (99.7%), ahead of Other Revenues at $306.00K (0.3%).
ImmunityBio began breaking out Product Revenue, Net in fiscal 2024, when it brought in $14.15M.
ImmunityBio (IBRX) reports its revenue by geography and by product and service. In fiscal 2025, U.S was its largest region, bringing in $113.01M (99.8% of the total), followed by Europe at $278.00K (0.2%).
U.S was ImmunityBio's largest region in fiscal 2025, bringing in $113.01M, or 99.8% of the $113.29M total across its two regions.
Product Revenue, Net was ImmunityBio's largest product and service line in fiscal 2025, bringing in $112.98M, or 99.7% of the $113.29M total across its two product and service lines.
Every figure comes from ImmunityBio's annual financial filings, as reported. Each line keeps the name ImmunityBio gives it, and years follow its fiscal calendar.
ImmunityBio's revenue by geography goes back to fiscal 2013, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.